Michael J. Morris, MD

home / authors / michael-j-morris-md

Articles

Targeted Radioligand Therapy Shows Efficacy in PSMA-Positive mCRPC

July 25th 2022

Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.

Phase1b Trial Investigates Atezolizumab and Radium-223 in mCRPC

Michael J. Morris, MD

September 3rd 2020

Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.

The Rationale of the TAX 3503 Trial in Prostate Cancer

Michael J. Morris, MD

August 5th 2014

Michael J. Morris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the rationale behind TAX 3503 (hormonal therapy +/- docetaxel for patients at high risk of metastatic prostate cancer).

The Uses of Biomarkers in Prostate Cancer Trials

Michael J. Morris, MD

May 31st 2013

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of biomarkers in prostate cancer clinical trials.

Using Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC

Michael J. Morris, MD

May 15th 2013

Michael J. Morris, MD, discusses an ongoing phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.